GW Pharmaceuticals rose 50 per cent to 59¾p on the back of clinical trial data that showed its lead drug, Sativex, had reduced spasticity in patients with multiple sclerosis.
GW said it would now seek approval from European regulators for the drug. "Given the regulator has seen most of this data before, we feel the approval process should be fairly quick and GW should see the result of its application within six months post filing," Investec Securities said.
